New obesity figures were recently announced.
And they’re not so good.
According to the World Health Organization, obesity has more than doubled since 1990. In fact, global adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. And over 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity.
While that’s not great for millions of obese people around the world, it’s great news for biotech stocks getting caught up in the drug treatment boom.
|
Company: Eli Lilly (SYM: LLY) The company is seeing so much demand it’s spending $5.3 billion to make even more Mounjaro and Zepbound. According to The Wall Street Journal, Zepbound alone is generating more than 78,000 prescriptions every week in the U.S. No wonder shares of LLY exploded from a January low of about $580 to $901.26. |
Financial Markets Daily
Little-known biotech company just had groundbreaking results from a study
As biotech stages a big comeback, one NYSE-traded company looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
>> Get the stock symbol here <<
|
Other top stocks to keep an eye on include: The company reported that the injectable form of its treatment helped patients lose up to 13.1% of their weight after 13 weeks in Phase 2 trials. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. Two, thanks to Viking’s success in obesity drug trials, analysts at BTIG just reiterated a buy rating with a price target of $125 a share. |
Oxford Club
AI’s Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
$1,000 in each turned into $1.18 million!
But the Man Who Called Nvidia at $1.10 Says “AI”s Next Magnificent Seven Could Do It Even Faster.”
He says $1,000 in these seven stocks could turn into $1 million+ in less than six years.
See His Breakdown of the Seven Stocks You Should Own Here.
|
Company: Altimmune (SYM: ALT) Recent Phase 2 results showed that patients lost an average of 15.6% of their body weight at 48 weeks at the highest dose. The study also found that the treatment led to better lean mass preservation as compared to other similar weight loss treatments. “Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function,” CEO Vipin Garg said in a news release. “We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.” |
Goldencrest Metals
Biden’s 44.6% Tax Bombshell: Protect Your Savings Now
Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025.
Click here to unlock your exclusive guide before it’s too late.
